Torrent Pharmaceuticals Ltd posted a robust 26% YoY net profit

posted a robust 26% YoY net profit jump to ₹635 Cr in Q3 FY26, driven by 17.6% revenue growth to ₹3,303 Cr and steady 32.9% EBITDA margins post-USFDA clearance of its Gujarat oncology facility with zero observations (Apr 6-10 inspection). NCLT approved shareholder meeting for J.B. Chemicals amalgamation on Apr 28, with e-voting Apr 24-27. Semaglutide launch in India (oral/injectable) expands diabetes portfolio.